{"nctId":"NCT00085202","briefTitle":"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor","startDateStruct":{"date":"2003-08"},"conditions":["Brain and Central Nervous System Tumors"],"count":416,"armGroups":[{"label":"Stratum 1 (high-risk group)","type":"EXPERIMENTAL","interventionNames":["Biological: filgrastim","Drug: cisplatin","Drug: cyclophosphamide","Drug: vincristine","Procedure: autologous hematopoietic stem cell transplantation","Radiation: radiation therapy"]},{"label":"Stratum 2 (average-risk group)","type":"EXPERIMENTAL","interventionNames":["Biological: filgrastim","Drug: cisplatin","Drug: cyclophosphamide","Drug: vincristine","Procedure: autologous hematopoietic stem cell transplantation","Radiation: radiation therapy"]}],"interventions":[{"name":"filgrastim","otherNames":["Neupogen(R)","G-CSF"]},{"name":"cisplatin","otherNames":["Platinol-AQ(R)"]},{"name":"cyclophosphamide","otherNames":["Cytoxan(R)"]},{"name":"vincristine","otherNames":["Oncovin(R)"]},{"name":"autologous hematopoietic stem cell transplantation","otherNames":["autologous HSCT"]},{"name":"radiation therapy","otherNames":["RT","Craniospinal radiotherapy"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed diagnosis of 1 of the following:\n\n  * Medulloblastoma\n  * Supratentorial primitive neuroectodermal tumor (PNET)\n  * PNET variants (ependymoblastoma, pineoblastoma, CNS neuroblastoma)\n  * Atypical teratoid rhabdoid tumor (ATRT)\n* Definitive surgery for CNS tumor within the past 31 days\n* Meets one of the following risk criteria:\n\n  * Average-risk disease\n\n    * Localized disease with no overt evidence of invasion beyond the posterior fossa (or supratentorial compartment for PNET or ATRT) by intraoperative observations of the neurosurgeon AND postoperative CT scan or MRI\n    * T4 disease eligible if all of the following are true:\n\n      * Gross total resection determined by intraoperative observations of the neurosurgeon AND postoperative CT scan or MRI\n      * Residual tumor or imaging abnormality whose size is \\< 1.5 cm\\^2\n      * No evidence of CNS or extraneural metastasis by MRI of the spine (with and without contrast agent) or CT-based myelogram AND by cytologic examination of the lumbar cerebral spinal fluid (CSF) 14-28 days after surgery\n    * Brain stem invasion allowed in the absence of residual tumor (tumor \\< 1.5 cm\\^2 by imaging)\n  * High-risk disease meeting one of the following criteria:\n\n    * Metastatic disease within the neuraxis (i.e., evidence of subarachnoid dissemination by imaging and/or cytologic examination of CSF)\n    * Presence of residual disease \\> 1.5 cm\\^2 at the primary site after surgery\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 3 to 21 at diagnosis\n\nPerformance status\n\n* Lansky 30-100% (\\< 10 years old)\n* Karnofsky 30-100% (â‰¥ 10 years old) (except for posterior fossa syndrome)\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Hemoglobin \\> 8 g/dL\n* WBC \\> 2,000/mm\\^3\n* Absolute neutrophil count \\> 500/mm\\^3\n* Platelet count \\> 50,000/mm\\^3\n\nHepatic\n\n* ALT \\< 5 times normal\n* Bilirubin \\< 3.0 mg/dL\n\nRenal\n\n* Creatinine \\< 2.0 mg/dL OR\n* Creatinine clearance \\> 70 mL/min\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No prior chemotherapy\n\nEndocrine therapy\n\n* Prior corticosteroid therapy allowed\n\nRadiotherapy\n\n* No prior radiotherapy\n\nSurgery\n\n* See Disease Characteristics","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors","description":"The relationship between ERBB2 protein expression in tumors and progression-free survival was assessed in 122 participants with a diagnosis of medulloblastoma and with ERBB2 protein assessments. If the ERBB2 value was greater than zero, the ERBB2 was defined as positive for the participant. If the ERBB2 value was zero, the ERBB2 was defined as negative. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"69.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"93.5","spread":null},{"groupId":"OG002","value":"71.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.","description":"122 participants with a diagnosis of medulloblastoma were grouped by ERBB2 positive/negative assessment and risk group into 4 groups. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"69.6","spread":null},{"groupId":"OG002","value":"93.5","spread":null},{"groupId":"OG003","value":"71.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Frequency of Mutations Associated With SHH and WNT Tumors","description":"The frequency of mutations for the main genes associated with SHH and WNT tumors identified via targeted sequencing based on formalin fixed paraffin embedded material is provided.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"7","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"18","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Reading Decoding Composite Scores in the Intervention and Standard of Care Groups","description":"SOC is standard-of-Care control group. Patients randomly assigned to the control group received the current standard of care. RI is Reading Intervention Group. Patients randomly assigned to Reading Intervention Group which is with The Fast ForWord program. Assessment of reading decoding was completed using the Woodcock Johnson, Third Edition (WJIII) Tests of Achievement (Woodcock, McGraw, \\& Mather, 2001), with particular attention given to the reading and reading-related abilities. Two subtests were completed: (1) Letter-Word Identification, and (2) Word Attack, a test requiring the patient to read phonologically regular nonwords. The combination of these two subtests provided a standardized composite score of overall reading decoding ability with a population mean of 100 and a standard deviation of 15. Scores of 90-110 are considered to be in the average range, while those 80-89 are considered low-average (refer: Journal of Pediatric Psychology 39(4) pp. 450-458, 2014).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.1","spread":"1.902"},{"groupId":"OG001","value":"102.4","spread":"2.604"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.51","spread":"0.4849"},{"groupId":"OG001","value":"-1.17","spread":"0.4883"}]}]}]},{"type":"SECONDARY","title":"Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa","description":"To monitor for treatment failure in the posterior fossa of patients whose tumor bed receives a reduced volume of radiation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Associative Memory for Two Risk Group at Enrollment","description":"Assessment of associative memory at enrollment. Associate memory score is a representative measurement of learning and recalling pictograph representations of words. It measures associative memory (Long-Term Retrieval). Mean=100, SD=15, Average Range 85-115. Higher is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.61","spread":"22.25"},{"groupId":"OG001","value":"98.04","spread":"18.56"}]}]}]},{"type":"SECONDARY","title":"Associative Memory for Two Risk Group at 5 Years After Enrollment","description":"Assessment of associative memory at 5 years after enrollment. Assessment of associative memory score at enrollment. Associate memory score is a representative measurement of learning and recalling pictograph representations of words. It measures associative memory (Long-Term Retrieval). Mean=100, SD=15, Average Range 85-115. Higher is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.73","spread":"16.94"},{"groupId":"OG001","value":"93.58","spread":"13.7"}]}]}]},{"type":"SECONDARY","title":"Processing Speed for Two Risk Group at Enrollment","description":"Assessment of Processing Speed at enrollment. This score measure of Processing Speed based on Visual Matching and Decision Speed tests. Mean=100, SD=15, Average Range 85-115. Higher is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.98","spread":"18.53"},{"groupId":"OG001","value":"87.29","spread":"19.73"}]}]}]},{"type":"SECONDARY","title":"Processing Speed for Two Risk Group at 5 Years After Enrollment","description":"Assessment of Processing Speed at 5 years after enrollment. This score measure of Processing Speed based on Visual Matching and Decision Speed tests. Mean=100, SD=15, Average Range 85-115. Higher is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.21","spread":"24.36"},{"groupId":"OG001","value":"75.71","spread":"25.71"}]}]}]},{"type":"SECONDARY","title":"Perceptual Speed for Two Risk Group at Enrollment","description":"Assessment of Perceptual Speed at enrollment. It measures rapidly locating and circling identical numbers from a set of numbers which reflects perceptual speed. Mean=100, SD=15, Average Range 85-115. Higher is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.06","spread":"19.99"},{"groupId":"OG001","value":"90.04","spread":"18.23"}]}]}]},{"type":"SECONDARY","title":"Perceptual Speed for Two Risk Group at 5 Years After Enrollment","description":"Assessment of Perceptual Speed at 5 years after enrollment. It measures rapidly locating and circling identical numbers from a set of numbers which reflects perceptual speed. Mean=100, SD=15, Average Range 85-115. Higher is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.68","spread":"21.58"},{"groupId":"OG001","value":"72.29","spread":"27.32"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":269},"commonTop":["Febrile neutropenia","Infection, blood","Vomiting","Allergic reaction/hypersensitivity (including drug fever)","Pain, abdomen NOS"]}}}